Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 22Recruiting 12Active not recruiting 10Withdrawn 5Terminated 3Unknown 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lung Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Ototoxicity 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Mesothelioma 1Hepatoblastoma 1Chemotherapeutic Agent Toxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Radiotherapy 1Radiation 1Platinum 1Monatide (IMS 3015) 1Magnetic Resonance Spectroscopy 1Infusions, Parenteral 1Hyperthermic Intraperitoneal Chemotherapy 1Cisplatin 1Biological Assay 1ALT-803 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma × Cisplatin × Clear all
NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡